{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:47:18Z","timestamp":1794491238417,"version":"4.9.1"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.1001\/jamaophthalmol.2022.0663","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:49:51Z","timestamp":1649332191000},"page":"480","source":"Crossref","is-referenced-by-count":34,"title":["Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US"],"prefix":"10.1001","volume":"140","author":[{"given":"Mahyar","family":"Etminan","sequence":"first","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Sodhi","sequence":"additional","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Mikelberg","sequence":"additional","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maberley","sequence":"additional","affiliation":[{"name":"Collaboration for Epidemiology of Ocular Diseases (CEPOD), Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Department of Ophthalmology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"eoi220014r1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/WNO.0000000000000450","article-title":"Food and Drug Administration adverse event reports of retinal vascular occlusions associated with phosphodiesterase type 5 inhibitor use.","volume":"36","author":"Li","year":"2016","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"eoi220014r2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ajo.2006.10.006","article-title":"Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.","volume":"143","author":"Margo","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi220014r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/WNO.0000000000000186","article-title":"Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy.","volume":"35","author":"Nathoo","year":"2015","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"eoi220014r4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jsm.12726","article-title":"Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.","volume":"12","author":"Campbell","year":"2015","journal-title":"J Sex Med"},{"issue":"5","key":"eoi220014r5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ceo.2009.37.issue-5","article-title":"Phosphodiesterase inhibitors and the eye.","volume":"37","author":"Kerr","year":"2009","journal-title":"Clin Exp Ophthalmol"},{"issue":"11","key":"eoi220014r6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.oret.2020.06.006","article-title":"Prospective impact of sildenafil on chronic central serous chorioretinopathy: PISCES trial.","volume":"4","author":"Breazzano","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"eoi220014r7","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1007\/s11606-021-06968-2","article-title":"Marked increase in sales of erectile dysfunction medication during COVID-19.","volume":"36","author":"Hernandez","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"12","key":"eoi220014r9","doi-asserted-by":"publisher","DOI":"10.1136\/oem.2004.014472","article-title":"An incidence density sampling program for nested case-control analyses.","volume":"61","author":"Richardson","year":"2004","journal-title":"Occup Environ Med"},{"issue":"5","key":"eoi220014r10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archopht.120.5.601","article-title":"Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy.","volume":"120","author":"Mojon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"eoi220014r11","doi-asserted-by":"publisher","author":"Chen","year":"2015","DOI":"10.1371\/journal.pone.0132510"},{"issue":"4","key":"eoi220014r16","first-page":"249","article-title":"Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.","volume":"51","author":"Pinto","year":"2009","journal-title":"Indian J Chest Dis Allied Sci"},{"issue":"2","key":"eoi220014r17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0039-6257(99)00079-X","article-title":"Sildenafil (Viagra) and ophthalmology.","volume":"44","author":"Marmor","year":"1999","journal-title":"Surv Ophthalmol"},{"key":"eoi220014r8","unstructured":"IQVIA PharMectrics Plus. Fact sheet. IQVIA; 2020. Accessed November 7, 2021. https:\/\/www.greygreenmedia.com\/app\/uploads\/sites\/2\/2020\/09\/IQVIA-PharMetrics-Plus-US-Fact-Sheet.pdf"},{"key":"eoi220014r12","unstructured":"Sildenafil. Product monograph. Pharmascience Inc; 2018. Accessed February 7, 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00048380.PDF"},{"key":"eoi220014r13","unstructured":"Tadalafil. Product monograph. Eli Lilly Canada Inc; 2020. Accessed February 7, 2022. https:\/\/pi.lilly.com\/ca\/cialis-ca-pm.pdf"},{"key":"eoi220014r14","unstructured":"Vardenafil. Product monograph. Bayer Inc; 2020. Accessed February 7, 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00055199.PDF"},{"key":"eoi220014r15","unstructured":"Avanafil. Product monograph. VIVUS, Inc; 2012. Accessed February 7, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202276s000lbl.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2790661\/jamaophthalmology_etminan_2022_oi_220014_1651869686.78153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T11:04:03Z","timestamp":1652958243000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2790661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.0663","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741945840.793592746","asserted-by":"object"}]},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}